ABUS — Arbutus Biopharma Corp
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1447028 ·
Last close
$4.64
Market Cap
$916.57M
52W High
$4.85
52W Low
$4.01
ADV30
1,741,683
Next earnings
2026-08-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 179,126,000 | — | 169,117,000 | 169,695,000 | 277,164,000 | 23,706,000 | 16,987,000 |
| Dec 2025 | 1,051,000 | — | -7,644,000 | -3,756,000 | 94,618,000 | 18,008,000 | 18,042,000 |
| Sep 2025 | 529,000 | — | -8,293,000 | -7,742,000 | 97,710,000 | 22,408,000 | 20,311,000 |
| Jun 2025 | 10,739,000 | — | 1,913,000 | 2,523,000 | 103,267,000 | 37,412,000 | 20,291,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-39,637,000
Investing CF
$15,580,000
Financing CF
$5,721,000
CapEx
$-86,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.26
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,380,073,000
Inventory
—
Receivables
$1,447,000
ST Investments
$73,463,000
EBIT TTM
$-33,404,000
Pretax Income TTM
$-33,501,000
Interest Exp TTM
$97,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$191,444,992
EBITDA
$155,136,992
Free Cash Flow
$-90,406,624
Enterprise Value
$825,257,984
Total Cash
$95,226,000
Total Debt
$3,909,000
Shares Out
197,537,710
Trailing EPS
$0.83
Book Value
$1.32
ROE
94.7%
ROA
49.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 14,083,000 | -27,051,000 | -33,501,000 | 94,618,000 | 18,042,000 | — | -39,637,000 |
| Dec 2024 | 6,171,000 | -69,974,000 | -69,920,000 | 131,707,000 | 34,341,000 | — | -64,850,000 |
| Dec 2023 | 18,141,000 | -78,034,000 | -72,849,000 | 144,401,000 | 38,383,000 | — | -85,936,000 |
| Dec 2022 | 39,019,000 | -63,223,000 | -69,456,000 | 195,419,000 | 58,567,000 | — | -35,356,000 |
TTM Snapshot
Revenues TTM
$15,289,000
NetIncome TTM
$-76,546,000
OpCashFlow TTM
$0
Assets (Latest)
$131,707,000
Forward EPS
$-0.17
Max Pain — expiry 2026-06-18
max pain strike: $4.00 · spot: $4.64 · call oi: 4,596 · put oi: 5,185
Expected Move to 2026-06-18:
±$0.72
(15.63%) —
implied range
$3.91 –
$5.36
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LXRX | LEXICON PHARMACEUTICALS, INC. | $915.04M | $2.06 | — |
| KURA | Kura Oncology, Inc. | $924.14M | $10.41 | — |
| ANNX | Annexon, Inc. | $904.41M | $5.52 | — |
| PHAT | Phathom Pharmaceuticals, Inc. | $885.29M | $11.10 | — |
| ORIC | Oric Pharmaceuticals, Inc. | $884.04M | $8.54 | — |
News headlines (Yahoo Finance, 1h cache)
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-13 11:30 · Yahoo
The Zacks Analyst Blog Highlights Moderna, Merck and Vertex Pharmaceuticals
2026-05-04 06:49 · Yahoo
Moderna’s Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway.
2026-05-01 18:35 · Yahoo
Moderna Reports Q1 Loss, Stock Jumps on Strong International Sales
2026-05-01 15:32 · Yahoo
Moderna Q1 2026 earnings beat on international COVID vaccine sales
2026-05-01 13:05 · Yahoo
Moderna sees revenue bump from international COVID vaccine sales
2026-05-01 12:27 · Yahoo
Arbutus Biopharma (ABUS): 10 Best Biotech Penny Stocks to Buy in 2026
2026-05-01 09:22 · Yahoo
Arbutus Biopharma (ABUS) Wins FDA Fast Track for Imdusiran
2026-04-23 07:29 · Yahoo
Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability
2026-04-17 13:58 · Yahoo
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
2026-04-15 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.